Photo: calvinfleming via flickr
WASHINGTON (AP) — The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumour cells while sparing healthy ones.
The drug Kadcyla (kad-SY’-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy and a third chemical linking the medicines together. The chemical keeps the drugs intact until they bind to a cancer cell, where the double-shot of medication is released.
The FDA approved the drug for about 20 per cent of breast cancer patients who have a particular form of the disease. These patients have tumors that overproduce the protein HER-2.
The approval will help Roche build on the success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of $6 billion last year.
Copyright (2013) Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Associated Press text, photo, graphic, audio and/or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. Neither these AP materials nor any portion thereof may be stored in a computer except for personal and non-commercial use. Users may not download or reproduce a substantial portion of the AP material found on this web site. AP will not be held liable for any delays, inaccuracies, errors or omissions therefrom or in the transmission or delivery of all or any part thereof or for any damages arising from any of the foregoing.
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.